Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
7 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Hematologic Autoimmune Manifestation Secondary to Coronavirus Disease 19 Infection – A Single-Center Experience(Scientific Foundation Spiroski (publications), 2021-09-11); ; BACKGROUND: Since December 2019, multiple human cases of novel coronavirus infection were reported, representing with upper respiratory symptoms (influenza-like presentation). The virus was named the severe acute respiratory system coronavirus 2 (SARS-COV-2). Studies have reported cases of patients with coronavirus disease 19 (COVID-19) infection, including development of several autoimmune events that suggest that infection with SARS-CoV-2 may be associated with initiation of autoimmune hematological autoimmune disorders.AIM: This study aims to review the hematological autoimmune phenomena after infection with SARS-CoV-2 to assist into the pathogenic mechanisms, clinical manifestations, and treatment of this group of patients.MATERIALS AND METHODS: This is a retrospective study that includes 21 patients with autoimmune diseases such as secondary immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and thrombotic thrombocytopenic purpura (TTP) that have emerged after COVID-19 infection. The patients were diagnosed and treated at the University Clinic of Hematology-Skopje for a period of time from January 2020 to April 2021.RESULTS: The most common hematologic autoimmune disorder was ITP in 13 cases (62%) followed by AIHA in 5 cases (24%) and TTP in 3 individuals (14%). The mean time of onset of the hematologic autoimmune presentations was 18.4 ± 10.3 days. The therapy of this condition in patients with COVID-19 infection requires an individualized approach to achieve a precise balance between the risk of severe bleeding and of thromboembolic events.CONCLUSION: Causal relationship between COVID-19 infection and these autoimmune events still requires further studies. We should all have in mind the risk of development of hematologic autoimmune disorders in infected patiens - Some of the metrics are blocked by yourconsent settings
Item type:Publication, MM-326: Visceral Leishmaniasis Mimicking Multiple Myeloma(Elsevier BV, 2021-09); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, OBINUTUZUMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: SINGLE CENTER EXPERIENCE(Faculty of Medicine, UKIM, Skopje, 2023); ; ; ; Popova Labacevska, MarijaMonoclonal antibodies (mAbs) targeting CD20 molecule on B lymphocyte are of great importance in the treatment of B-cell malignancies. In recent years a great effort has been put in developing novel mAbs that can provide greater efficacy than the well-known rituximab. A second class of mAbs obinutuzumab has been presented as a more powerful tool in the treatment of this group of patients. In this retrospective study 70 patients with symptomatic CLL were included. CLL patients were diagnosed and treated at the University Clinic for Hematology between January 2018 and January 2022. All patients were evaluated for traditional clinical and laboratory prognostic factors and newer prognostic factors including IGHV mutation status and CLL prognostic and predictive genetic abnormalities. Most of the patients treated with obinutuzumab had Binet B stage (56%). Mutational status of the immunoglobulin variable region heavy chain (IGHV) in most of CLLpatients treated with obinutuzumab was unmated IGHV gene. The most frequently encountered adverse events were tumor lysis syndrome and leukopenia. The analysis of the initial results of the application of obinutuzumab-based therapy allows us to conclude that this therapeutical modality is not associated with severe adverseevents that would limit the administration of therapy. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, CHRONIC LYMPHOCYTIC LEUKEMIA ARISING IN A PATIENT WITH HODGKIN LYMPHOMA TREATED WITH PERIPHERAL BLOOD STEM CELL TRANSPLANTATION - Case report(Macedonian Association of Anatomists, 2022-06); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, PREDICTIVE INSTRUMENT FOR ASYMPTOMATIC EARLY-STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS-SINGLE CENTRE EXPERIENCE(Macedonian Association of Anatomists, 2021-12-28); ; ; ; Stojanovska, SimonaEarly-stage patients with Chronic lymphocytic leukemia (CLL) are diagnosed without need for treatment, managed with following. The distinct course of the disease is diverse, and planing treatment is barely projected at diagnosis. The aim of the study was first-time evaluation of international prognostic score to predict time to first treatment (TFT) in patients with early stage CLL (International Prognostic Score for Early-stage CLL IPS-E). Retrospective study of asymptomatic patients with CLL at early stage of disease in a period of time from January 2011 to January 2021. The median follow-up was 60 months (1-120 months). Individual patient data from 120 treatment-naïve CLL patients with Binet A stage were analyzed to composed International Prognostic Score for Early-stage CLL and correlated with Time to treatment failure (TTF). Using IPS-E patients were distributed in three groups: low risk with 7, 5%, intermediate risk with 44 % and high risk patients 49%. Average TFS was 29, 3 months for low risk group, 28, 6 months for intermediate-risk group and 27,1 months for high-risk group. Using prognostic nomogram we calculated 5 years probability of survival for low, intermediate and high risk group: 73%, 72% and 70% respectively with projected median survival of 9, 1 year for low risk group and 9, 0 year, 8, 9 years for intermediate and high risk groups. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Early mortality and overall survival in acute promyelocytic leukemia – a single-center experience(Macedonian Pharmaceutical Association, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy, 2021-07); ; ; ; Acute promyelocytic leukemia (APL) is a subtype of acute leukemia (AL) with distinct cytogenetics, clinical and biological characteristics. APL was considered as one of the most rapidly lethal forms of acute myeloblastic leukemia (AML), but recently, with the introduction of all-trans retinoic acid (ATRA) it has become the most curable subtype of AL. The main difficulty with APL is early death (ED), defined as death because of any cause within 30 days after diagnosis, and it has emerged as the most important cause of treatment failure. Our retrospective-prospective study was realized at the University Clinic for Hematology from January 2004 until December 2020. It included 46 patients with APL, according to FAB and WHO classification with confirmed molecular diagnosis. The following patients’ risk stratification factors were analyzed: age, Sanz risk score, WBC, PL, clinical presentation of the disease, levels of fibrinogen and Ddimers. During the study period, APL was diagnosed in 46 patients, 24 females (52.2%) and 22 males (47.8%), with mean age of 45 years. The overall survival showed that 24 patients (52.1%) were alive and 22 (47.8%) had lethal outcome. Regarding treatment, five patients (10.9%) died before starting the chemo-treatment. But, still, ED was observed in 13 patients (59%), and in 9 patients (40.9%) death occurred 30 days after establishing the diagnosis. The main reasons of mortality were also analyzed. To prevent ED prior to treatment, suspected APL patients should be immediately hospitalized and treated as medical emergency. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Analysis of Prognostic Factors As Predictors of Treatment Free Survival in Patients with Chronic Lymphocytic Leukemia-Single Centre Experience(2021-08); ; ; ; Krstevska-Balkanov, SvetlanaIntroduction: Chronic lymphocytic leukemia (CLL) is a heterogeneous clonal lymphoproliferative disease originating from activated B lymphocytes that have experienced antigen. The clinical course is very heterogeneous. Some patients never look for treatment, as opposed to others who live and die with an aggressive illness. This clinical heterogeneity is likely a reflection of molecular and cellular heterogeneity, on the basis of which patients with CLL can be divided into subgroups with different clinical-biological characteristics. Aim of the study: Evaluation of prognostic factors in terms of treatment free survival, prognosis and adequate therapeutic approach in patients with CLL. Material and methods: The study is set as retrospective, it includes 300 patients with CLL diagnosed and treated at the University Clinic of Hematology in the period of 10 years (January 2009 - January 2019). The study was performed at the University Clinic for Hematology, Medical Faculty, Ss. Cyril and Methodius University, Skopje, Republic of North Macedonia. We evaluate several prognostic factors in terms of treatment free survival. All results were processed with the statistical program SPSS18 software program. Results: The multivariate Cox Proportional model of Treatment free survival of CLL patients confirmed ECOG, Rai Stage, and spleen size that influence on treatment free survival.. Concusion: In our study, multivariate analysis of treatment free survival and overall survival showed ECOG performance status 0,1 and 2 as a factor influencing both overall survival and treatment free survival